

4DMedical signs contract to expand in Western Australia

2 December 2024

Highlights

- 4DMedical signs contract with Perth Radiological Clinic (PRC) to deploy its breakthrough XV Technology[®]-enabled ventilation reports across 16 clinics in Perth
- PRC is a leading diagnostic imaging provider in Western Australia, serving a significant share of the Perth market, making this partnership a major milestone in 4DMedical's Australian expansion strategy
- Engagement with PRC was accelerated following the RANZCR Annual Scientific Meeting, where 4DMedical's presentation to PRC's chest radiologists highlighted the clinical benefits of XV Technology[™]

Melbourne, Australia, 2 December 2024: 4DMedical Limited (ASX: 4DX) ("4DMedical" or the "Company"), a leader in respiratory imaging technology, today announces it has signed a commercial contract with Perth Radiological Clinics (PRC) to deliver its breakthrough XV Technology[®]-enabled ventilation reports across an initial 16 clinics in Perth. This agreement marks an important milestone in the expansion of 4DMedical's presence across the Australian healthcare market.

Contract with Perth Radiological Clinic

PRC is a leading provider of diagnostic imaging services in Western Australia, known for its clinical excellence and strong market presence. With over 20 clinics strategically located across Perth, PRC services a significant proportion of the region's population, including leading public and private healthcare providers.

The engagement with PRC was catalysed by 4DMedical's presentation at the Royal Australian and New Zealand College of Radiologists (RANZCR) Annual Scientific Meeting held in Perth earlier this year. At the event, 4DMedical showcased the transformative potential of XV Technology[®] to PRC's chest radiology team, receiving overwhelmingly positive feedback on its ability to deliver unprecedented functional lung imaging. As such, the adoption of XV Technology[®] by PRC represents a strong endorsement of the clinical utility of 4DMedical's groundbreaking technology.

The contract with PRC allows referring doctors to order both CT LVAS[™] ventilation reports via widely available Computed Tomography (CT) imaging infrastructure and XV LVAS[®] ventilation reports via fluoroscopy, empowering PRC's radiology team to deliver advanced diagnostic insights. Scans will be delivered and billed on a Software-as-a-Service (SaaS) model in line with those of 4DMedical's other partners. The initial term of the contract will run until 30 September 2025.

Momentum continues with expansion of practices

This contract accelerates 4DMedical's growth strategy in Australia while further solidifying its reputation as a pioneer in respiratory imaging. With PRC joining the growing network of users, 4DMedical continues to lead the transformation of respiratory diagnostics, ensuring clinicians have access to cutting-edge tools for patient care.

This announcement coincides with our presence at the 2024 RSNA Annual Meeting, where 4DMedical will deliver a Centre Stage Presentation at the Innovation Theater on December 3, titled *"Innovation, Partnerships—for Lung Health and Veterans: Philips and 4DMedical."* The session will highlight a collaboration aimed at advancing lung health diagnostics, particularly for Veterans exposed to airborne



hazards. Presented by 4DMedical CEO Prof. Andreas Fouras and Philips' Jeff DiLullo, the discussion will focus on leveraging lung imaging to improve care accessibility and outcomes for patients, especially in Veterans, and emphasising innovation and future growth.

For more details, visit 4DMedical.com/RSNA/.

4DMedical MD/CEO and Founder, Andreas Fouras, said:

We are delighted to partner with PRC, a leader in diagnostic imaging in Western Australia. This collaboration underscores the value and demand for XV Technology® in enhancing respiratory diagnostics. The engagement with PRC following our presentation at the RANZCR Annual Scientific Meeting highlights the growing recognition of 4DMedical's innovations among radiologists and healthcare providers alike. We look forward to supporting PRC in delivering world-class respiratory care to the Perth community.

With back-to-back commercial wins with UCSD and IPOC, our commercial operations are clearly building momentum. Combined with an exciting RSNA and new partnerships, I expect this momentum to continue to build and I look forward to continuing to bring you news of this growth over the remainder of this year and into the New Year.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity, and more personalised care for patients.

To learn more, please visit www.4dmedical.com